Stocks股票 / Health Care / ZBH
ZBH US listed · USD美股 · 美元
Zimmer Biomet Holdings, Inc. is a publicly traded American medical device company.捷迈邦美控股有限公司(Zimmer Biomet Holdings, Inc.)是一家美国上市医疗器械公司。
Price chart价格图表
Technicals技术面
daily bars日线数据 · 2026-07-21Earnings财务业绩
next report下次财报 2026-08-06Estimates being cut预期下调
Post-earnings drift: -2.1% (20d)财报后漂移:-2.1%(20日)
Valuation估值
Looks cheap vs sector相对行业偏便宜| Multiple指标 | ZBH | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率(历史) | 24.90x | 28.59 | |
| P/B市净率 | 1.38x | 3.44 | |
| P/S市销率 | 2.13x | 2.97 | |
| Earnings yield盈利收益率 | 4.02% | 2.72 | |
| FCF yield自由现金流收益率 | 8.39% | 4.00 | |
| Shareholder yield股东收益率 | 3.86% | 1.89 | |
| EV/EBITDA企业价值/EBITDA | 11.17x | 18.18 | |
| P/FCF市值/自由现金流 | 11.92x | 22.08 |
Financials财务数据
fiscal years财年Leverage杠杆
Capital allocation资本配置
Why is it moving为何波动
6 checks · nightly六项检查 · 每晚Options positioning期权持仓
as of last close截至上一收盘Market makers are net long gamma — price pinned near current level做市商净持有正伽玛,价格倾向于在当前水平附近震荡
Ownership & smart money持仓与聪明钱
13FInsider activity:内部人动向: -$0.3M net (0 buyers, 2 sellers)-$0.3M 净值(0 买家,2 卖家)
Signal history信号历史
engine events引擎事件Company profile公司档案
Zimmer Biomet Holdings, Inc. is a publicly traded American medical device company.捷迈邦美控股有限公司(Zimmer Biomet Holdings, Inc.)是一家美国上市医疗器械公司。
Demand chain:需求链: Contracted bookings (RPO) unclear (n/a YoY to ~$0B) — signed demand locked in ahead of recognition已签约订单(RPO)不明(同比n/a,约 $0B)——已锁定、尚未确认的需求
- Margin compression despite revenue growth
The whole US universe — S&P 1500 and Russell 2000 — read nightly.覆盖标普1500与罗素2000全部成分股 — 每晚更新解读。
Signals, options positioning, smart-money moves and factor DNA — the same engine that wrote this page covers 2,700+ US stocks.信号、期权持仓、聪明钱动向与因子基因 — 撰写本页的引擎覆盖2700多只美股。
Valuation vs sector估值对比行业
| Multiple指标 | This stock本股 | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率(静态) | 24.9× | 28.6× | 61% |
| Price / Book市净率 | 1.4× | 3.4× | 90% |
| Price / Sales市销率 | 2.1× | 3.0× | 61% |
| EV / EBITDAEV/EBITDA | 11.2× | 18.2× | 85% |
| Earnings yield盈利收益率 | 4.0% | 2.7% | 71% |
| Free-cash-flow yield自由现金流收益率 | 9.7% | 5.5% | 86% |
| Shareholder yield股东综合回报率 | 3.9% | 1.9% | 77% |
Relative strength相对强度
Price history价格历史
| Period周期 | This stock本股 | S&P 500标普500 |
|---|---|---|
| 1 Week近1周 | -4.6% | -0.9% |
| 1 Month近1月 | +2.3% | -0.6% |
| 3 Months近3月 | -3.2% | +5.4% |
| 6 Months近6月 | +3.9% | +8.6% |
| Year to date年初至今 | -0.1% | +8.9% |
| 1 Year近1年 | -3.0% | +19.2% |
Trading information交易信息
Multi-year record多年财务记录
| 20202020 | 20212021 | 20222022 | 20232023 | 20242024 | 20252025 | |
|---|---|---|---|---|---|---|
| Revenue营业收入 | $7.0B | $7.8B | $6.9B | $7.4B | $7.7B | $8.2B |
| EPS每股收益 | $-0.67 | $1.91 | $1.10 | $4.88 | $4.43 | $3.55 |
| Free cash flow自由现金流 | $1.1B | $1.3B | $1.2B | $1.3B | $1.3B | $1.5B |
| Gross margin毛利率 | 69.7% | 70.1% | 70.9% | 71.8% | 71.5% | 69.7% |
| Net margin净利率 | -2.0% | 5.1% | 3.3% | 13.8% | 11.8% | 8.6% |
| FCF margin自由现金流利润率 | 15.5% | 16.9% | 16.8% | 17.5% | 16.9% | 17.9% |
Latest fiscal year最近财年
Returns & growth回报与增长
Accounting quality checks会计质量检查
- Earnings quality: accruals near the peer median盈利质量:应计利润接近同业中位
- Working capital: working capital roughly in line with sales营运资本:营运资本与销售大致同步
- Pricing power: profitability near the peer median定价能力:盈利能力接近同业中位
- Capital discipline: investment near the peer median资本纪律:投资力度接近同业中位
- Balance sheet: Altman Z 2.36 — grey zone资产负债表:Altman Z 2.36——灰色区